Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:BCRX NASDAQ:HALO NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$41.22-2.5%$34.77$25.17▼$42.83$7.03B0.382.22 million shs2.40 million shsBCRXBioCryst Pharmaceuticals$8.39-2.2%$9.13$6.00▼$11.31$2.26B0.574.97 million shs3.08 million shsHALOHalozyme Therapeutics$66.21-2.8%$66.24$51.06▼$82.22$7.89B0.881.83 million shs2.39 million shsRGENRepligen$120.14-2.4%$118.05$100.99▼$175.77$6.99B1.091.34 million shs695,090 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+0.19%+14.86%+26.63%+44.76%+37.02%BCRXBioCryst Pharmaceuticals-3.82%+3.38%-6.75%-1.38%-20.13%HALOHalozyme Therapeutics+2.40%-0.26%+6.54%-1.82%+21.72%RGENRepligen-0.69%+6.99%+5.03%+0.03%+4.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$41.22-2.5%$34.77$25.17▼$42.83$7.03B0.382.22 million shs2.40 million shsBCRXBioCryst Pharmaceuticals$8.39-2.2%$9.13$6.00▼$11.31$2.26B0.574.97 million shs3.08 million shsHALOHalozyme Therapeutics$66.21-2.8%$66.24$51.06▼$82.22$7.89B0.881.83 million shs2.39 million shsRGENRepligen$120.14-2.4%$118.05$100.99▼$175.77$6.99B1.091.34 million shs695,090 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+0.19%+14.86%+26.63%+44.76%+37.02%BCRXBioCryst Pharmaceuticals-3.82%+3.38%-6.75%-1.38%-20.13%HALOHalozyme Therapeutics+2.40%-0.26%+6.54%-1.82%+21.72%RGENRepligen-0.69%+6.99%+5.03%+0.03%+4.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.76Moderate Buy$45.4010.14% UpsideBCRXBioCryst Pharmaceuticals 2.75Moderate Buy$20.70146.87% UpsideHALOHalozyme Therapeutics 2.50Moderate Buy$80.6721.83% UpsideRGENRepligen 2.88Moderate Buy$164.6437.04% UpsideCurrent Analyst Ratings BreakdownLatest BCRX, HALO, RGEN, and ALKS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026RGENRepligen Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$145.005/14/2026RGENRepligen Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$160.005/14/2026RGENRepligen Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy5/13/2026ALKSAlkermes Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $48.005/12/2026HALOHalozyme Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Buy (B-)5/12/2026HALOHalozyme Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$96.00 ➝ $93.005/11/2026ALKSAlkermes Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/7/2026RGENRepligen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/7/2026BCRXBioCryst Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$25.00 ➝ $28.005/7/2026BCRXBioCryst Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$22.00 ➝ $21.005/6/2026ALKSAlkermes UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $48.00(Data available from 6/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.48B4.66$1.64 per share25.20$11.02 per share3.74BCRXBioCryst Pharmaceuticals$874.84M2.44$1.16 per share7.20($0.57) per share-14.71HALOHalozyme Therapeutics$1.40B5.62$4.75 per share13.95$0.42 per share157.65RGENRepligen$738.26M9.18$3.31 per share36.28$37.42 per share3.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$241.66M$0.9046.9774.94N/A9.78%9.26%5.66%7/28/2026 (Estimated)BCRXBioCryst Pharmaceuticals$263.86M-$1.78N/A26.20N/A-51.71%-76.36%60.12%8/3/2026 (Estimated)HALOHalozyme Therapeutics$316.89M$2.7824.267.250.2723.13%187.91%21.92%8/4/2026 (Estimated)RGENRepligen$48.89M$0.90136.0049.242.396.73%4.88%3.48%8/4/2026 (Estimated)Latest BCRX, HALO, RGEN, and ALKS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026HALOHalozyme Therapeutics$1.54$1.60+$0.06$1.22$358.60 million$376.71 million5/6/2026Q1 2026BCRXBioCryst Pharmaceuticals$0.06-$2.98-$3.04-$2.98$151.12 million$156.41 million5/5/2026Q1 2026RGENRepligen$0.38$0.48+$0.10$0.15$192.05 million$194.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ABCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermes0.852.271.70BCRXBioCryst PharmaceuticalsN/A1.911.88HALOHalozyme Therapeutics8.812.762.33RGENRepligen0.269.207.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%BCRXBioCryst Pharmaceuticals85.88%HALOHalozyme Therapeutics97.79%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.59%BCRXBioCryst Pharmaceuticals3.80%HALOHalozyme Therapeutics2.50%RGENRepligen0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,050166.68 million159.03 millionOptionableBCRXBioCryst Pharmaceuticals530254.16 million244.51 millionOptionableHALOHalozyme Therapeutics390118.61 million115.65 millionOptionableRGENRepligen2,00056.41 million56.07 millionOptionableBCRX, HALO, RGEN, and ALKS HeadlinesRecent News About These CompaniesRepligen Has A Cleaner Recovery Angle, But With High ValuationMay 31 at 9:30 AM | seekingalpha.comRepligen Corp (RGEN) Stock Up 8.4% and Still Undervalued -- GF Score: 79/100May 28, 2026 | gurufocus.comRepligen Corporation (NASDAQ:RGEN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 27, 2026 | americanbankingnews.comGuggenheim Reaffirms Their Hold Rating on Repligen (RGEN)May 25, 2026 | theglobeandmail.comRepligen Corporation to Present at William Blair 46th Annual Growth Stock ConferenceMay 22, 2026 | globenewswire.comRepligen Announces Publication of the Company’s 2025 Corporate Sustainability ReportMay 20, 2026 | markets.businessinsider.comRepligen Announces Publication of the Company's 2025 Corporate Sustainability ReportMay 20, 2026 | globenewswire.comRepligen shares jump 4.1% as investors buy the dip after a sharp selloff; prior guidance update and short-covering may be factorsMay 19, 2026 | quiverquant.comQQ1 rundown: Repligen (NASDAQ:RGEN) vs other drug development inputs & services stocksMay 19, 2026 | msn.comRepligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To KnowMay 17, 2026 | finance.yahoo.com1 growth stock with explosive upside and 2 facing headwindsMay 15, 2026 | msn.com5 Revealing Analyst Questions From Repligen’s Q1 Earnings CallMay 15, 2026 | finance.yahoo.comRepligen Shareholders Approve Directors, Auditor and Pay PlanMay 15, 2026 | tipranks.comRepligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comBarclays Maintains an “Overweight Rating” on Repligen Corporation (RGEN)May 11, 2026 | insidermonkey.comSwedbank AB Invests $4.15 Million in Repligen Corporation $RGENMay 10, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Repligen (RGEN) and IQVIA Holdings (IQV)May 7, 2026 | theglobeandmail.comRepligen Corporation to Present at Bank of America Securities 2026 Global Healthcare ConferenceMay 7, 2026 | globenewswire.comJPMorgan Chase & Co. Lowers Repligen (NASDAQ:RGEN) Price Target to $165.00May 6, 2026 | marketbeat.comRepligen's Q1 Earnings & Revenues Beat Estimates, Stock RisesMay 6, 2026 | zacks.comRepligen Corporation $RGEN Stock Position Decreased by UBS Group AGMay 6, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026A Deep Dive Into NVIDIA’s Latest Portfolio MovesBy Leo Miller | May 19, 2026The Great Cloud Divide: How AI Is Reshuffling the Software DeckBy Jeffrey Neal Johnson | May 20, 2026Is Co-Diagnostics National Security’s Next Diagnostic Pick?By Jeffrey Neal Johnson | May 28, 2026BCRX, HALO, RGEN, and ALKS Company DescriptionsAlkermes NASDAQ:ALKS$41.22 -1.05 (-2.49%) As of 01:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.BioCryst Pharmaceuticals NASDAQ:BCRX$8.38 -0.19 (-2.16%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Halozyme Therapeutics NASDAQ:HALO$66.21 -1.93 (-2.83%) As of 01:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Repligen NASDAQ:RGEN$120.14 -2.96 (-2.40%) As of 01:22 PM Eastern This is a fair market value price provided by Massive. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for Investors How the Latest Federal Contract Boosts D-Wave's Prospects 5 Reasons to Pony Up for Pony AI Stock—and 1 Reason to Wait Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance MarketBeat Week in Review – 05/25 - 05/29 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
